Login
$GILD
$169.15 +$1.57 (0.94%) After hours

$GILD 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Results of Operations and Financial Condition

Product Sales Excluding Veklury Increased 16% Year-Over-Year to $8.2 Billion

04 Aug 2026 8-K: Results of Operations and Financial Condition

Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion

20 May 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

THIS ELEVENTH SUPPLEMENTAL INDENTURE is entered into as of May 20, 2026 (this “Eleventh Supplemental Indenture”) by and between Gilead Sciences, Inc., a corporation duly organized and existing under the laws of Delaware (herein called th...

07 May 2026 8-K: Results of Operations and Financial Condition

Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion

04 May 2026 8-K: Submission of Matters to a Vote of Security Holders

1.Purpose of the Plan. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company by offering them an opportuni...

28 Apr 2026 8-K: Regulation FD Disclosure; Other Events

FOSTER CITY, Calif., April 28, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acqu...

23 Feb 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

AGREEMENT AND PLAN OF MERGER among: ARCELLX, INC., a Delaware corporation; GILEAD SCIENCES, INC., a Delaware corporation; and RAVENS SUB, INC., a Delaware corporation

10 Feb 2026 8-K: Results of Operations and Financial Condition

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025

19 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

30 Oct 2025 8-K: Results of Operations and Financial Condition

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $7.1 billion

06 Oct 2025 8-K: Regulation FD Disclosure

On October 6, 2025, Gilead Sciences, Inc., a Delaware corporation (“Gilead”), announced that it has entered into settlement agreements (“Agreements”) to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., gen...

14 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

On August 10, 2025, the Board of Directors of Gilead Sciences, Inc., a Delaware corporation (the “Company”), appointed Erin Burkhart as Senior Vice President, Controllership and principal accounting officer of the Company, effective as o...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion

04 Aug 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle.

08 May 2025 8-K: Submission of Matters to a Vote of Security Holders

The 2025 annual meeting of stockholders (the “Annual Meeting”) of Gilead Sciences, Inc. (the “Company”) was held on May 7, 2025. Of the 1,246,634,469 shares of the Company’s common stock entitled to vote at the Annual Meeting, 1,121,336,...

24 Apr 2025 8-K: Results of Operations and Financial Condition

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion

12 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

11 Feb 2025 8-K: Results of Operations and Financial Condition

Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024

20 Nov 2024 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

THIS TENTH SUPPLEMENTAL INDENTURE, is entered into as of November 20, 2024 (this “Tenth Supplemental Indenture”) by and between Gilead Sciences, Inc., a corporation duly organized and existing under the laws of Delaware (herein called th...

06 Nov 2024 8-K: Results of Operations and Financial Condition

Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support